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Background: Bevacizumab, a humanized antibody to vascular endothelial growth factor (VEGF), shows clinical
activity against human cancer, with its addition to standard chemotherapy having been found to improve outcome
in patients with advanced nonsquamous non–small cell lung cancer (NSCLC). However, there have been no
evidence-based studies to support the continued use of bevacizumab beyond disease progression in such patients
treated with the drug in first-line therapy. We have now designed a randomized phase II trial to examine the
clinical benefit and safety of continued bevacizumab treatment in patients with advanced nonsquamous NSCLC
whose disease has progressed after first-line treatment with bevacizumab plus a platinum-based doublet.
Methods/Design: WJOG 5910L was designed as a multicenter, open-label, randomized, phase II trial by the West
Japan Oncology Group of docetaxel (arm A) versus docetaxel plus bevacizumab (arm B) in patients with recurrent
or metatstatic nonsquamous NSCLC whose disease has progressed after first-line treatment with bevacizumab plus
a platinum-based doublet. Patients in arm A will receive docetaxel at 60 mg/m2 and those in arm B will receive
docetaxel at 60 mg/m2 plus bevacizumab at 15 mg/kg, with each drug administered on day 1 every 21 days until
progression or unacceptable toxicity. The primary endpoint of the study is progression-free survival, with secondary
endpoints including response rate, overall survival, and safety, for patients treated in either arm.
Trial registration: UMIN (University Hospital Medical Information Network in Japan) 000004715
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Lung cancer is the most common cause of cancer-
related death worldwide, with non–small cell lung can-
cer (NSCLC) accounting for ~75% of all lung cancer
cases [1]. Platinum-based chemotherapy regimens are
the standard first-line treatment for individuals with
advanced NSCLC, but the efficacy of such regimens has* Correspondence: chi-okamoto@dotd.med.kindai.ac.jp
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reproduction in any medium, provided the orreached a plateau [2]. Both experimental and clinical
studies have identified many molecules that contribute
to the various biological behaviors of malignant tumors
including NSCLC.
Vascular endothelial growth factor (VEGF), an endo-
thelial cell–specific mitogen, is the major regulator of
angiogenesis in normal and malignant tissue [3,4].
Increased expression of VEGF has been detected in most
types of tumor in humans, including NSCLC, and, in
many instances, it is associated with increased risk of re-
currence, metastasis, or death [5-8]. Preclinical studiesLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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for VEGF inhibits the growth of human tumor xeno-
grafts when administered alone or together with chemo-
therapy [9-11]. A humanized variant of this antibody,
bevacizumab, has shown clinical activity against human
cancer, with its addition to standard chemotherapy
having been found to improve outcome in the treat-
ment of individuals with metastatic colorectal cancer
(mCRC) [12].
Randomized phase III trials have evaluated the
addition of bevacizumab to cytotoxic chemotherapy in
chemonaïve patients with advanced NSCLC. ECOG
4599 was the first of these trials and established the
combination of bevacizumab and cytotoxic chemother-
apy as a new standard of care for eligible patients [13].
This trial randomized 878 patients with NSCLC of stage
IIIb or IV to chemotherapy alone (carboplatin and pacli-
taxel) or the same chemotherapy regimen with bevacizu-
mab. Individuals with squamous cell carcinoma, brain
metastases, or hemoptysis and those receiving anticoa-
gulation therapy were excluded. Median overall survival
(OS) increased from 10.3 to 12.3 months as a result of
the addition of bevacizumab (hazard ratio [HR], 0.79;
P < 0.001), and median progression-free survival (PFS)
increased from 4.5 to 6.2 months (HR, 0.66; P < 0.001).
Toxicities that showed statistically significant but min-
imal increases in frequency associated with the addition
of bevacizumab included hypertension (6.0 versus 0.7%),
hemoptysis (1.9 versus 0.2%), and epistaxis (0.7 versus
0.2%) of grade ≥3 as well as neutropenia of grade 4 (25.5
versus 16.8%) and febrile neutropenia (5.2 versus 2.0%).
The AVAiL trial randomized patients to receive cisplatin
and gemcitabine alone or together with bevacizumab at
a dose of either 7.5 or 15 mg/kg [14]. Although OS was
originally selected as the primary endpoint, this was
changed to PFS during accrual. Like ECOG 4599, the ex-
clusion criteria of AVAiL were broad: a squamous tumor
histology, mixed adenosquamous histology if predomin-
antly squamous, hemoptysis greater than one-half tea-
spoon of bright red blood per event, tumor-invading or
abutting major blood vessels, brain metastases or spinal
cord compression, uncontrolled hypertension, throm-
botic or hemorrhagic disorders in the prior 6 months,
and therapeutic anticoagulation within 10 days of the
first dose. The median PFS was improved in both the
7.5 mg/kg group (6.7 months; HR, 0.75; P= 0.003) and
15 mg/kg group (6.5 months; HR, 0.82; P= 0.03) as com-
pared with the chemotherapy-alone arm (6.1 months).
OS was not significantly improved by the addition of
bevacizumab in this study.
On the basis of these results, bevacizumab plus cyto-
toxic chemotherapy has become a standard of care for
first-line therapy in a subgroup of patients with advanced
NSCLC. However, there are no evidence-based studies tosupport the use of bevacizumab beyond disease progres-
sion in NSCLC patients receiving the antibody as first-
line therapy. Preclinical studies have shown that VEGF is
expressed throughout the life cycle of a tumor [15,16],
and that VEGF inhibition results in marked antitumor
effects when the inhibitor is administered throughout
tumor development. Rapid tumor revascularization has
also been shown to occur after removal of anti-VEGF
therapy, suggesting that vascular regrowth may be a nor-
mal physiological response to the removal of VEGF in-
hibition [17,18]. Sustained VEGF inhibition has thus
been shown to achieve and maintain tumor regression.
Insight into the effect of treatment with bevacizumab be-
yond disease progression has been provided by the non-
randomized, prospective bevacizumab treatment registry
known as the BRiTE Study for mCRC [19]. In this pro-
spective study, the impact of treatment with bevacizumab
beyond first progression was examined. A total of 1445
patients manifested disease progression and received ei-
ther further treatment with bevacizumab (n= 642, 44%),
treatment other than bevacizumab (n= 531, 37%), or no
treatment (n= 253, 18%) after progression. Despite hav-
ing a patient population more representative of general
CRC patients, the group that continued bevacizumab be-
yond first tumor progression showed a median OS of
31.8 months (n= 642), compared with a median OS of
19.9 months for those patients who received treatment
other than bevacizumab (n= 531), a value similar to that
reported in previous randomized studies. On the basis of
these findings, the prospective European AIO 0504 trial
was undertaken and is currently under way for examin-
ation of the effect of the addition of bevacizumab to
fluoropyrimidine-based chemotherapy in patients with
mCRC who show disease progression while receiving
first-line standard chemotherapy plus bevacizumab.
With this background, the current randomized trial
(University Hospital Medical Information Network in
Japan [UMIN] 000004715) was designed to evaluate
whether the addition of bevacizumab to docetaxel alone
(the standard second-line treatment for NSCLC) might
improve PFS when administered as second-line treat-
ment in NSCLC patients who have progressed after




This open-label, randomized, phase II study of the
West Japan Oncology Group (WJOG 5910L) was
designed to evaluate the addition of bevacizumab to
standard therapy with docetaxel. The primary endpoint
of the study is PFS, with secondary endpoints
including response rate, OS, and safety, for patients
treated with either docetaxel alone or docetaxel plus
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stitutional ethics committee of each participating
institution.
Eligibility criteria
Study entry is limited to patients aged ≥20 years
with histologically or cytologically confirmed non-
squamous NSCLC that is either recurrent or meta-
static, with documented disease progression after
first-line treatment with bevacizumab plus platinum-
based doublet chemotherapy, and with an Eastern
Cooperative Oncology Group (ECOG) performance
status of 0 to 2. A patient who has received pre- or
postoperative chemotherapy is eligible if the last ad-
ministration of the prior adjuvant regimen occurred
at least 12 months before the onset of platinum-
based chemotherapy plus bevacizumab. A patient
with a history of treatment with epidermal growth
factor receptor (EGFR) tyrosine kinase inhibitors
(gefitinib or erlotinib) before platinum-based chemo-
therapy plus bevacizumab is also eligible if he or she
harbors an EGFR mutation. Adequate bone marrow,
renal, and liver function is required. A lesion not
previously irradiated that is measurable according to
the Response Evaluation Criteria in Solid Tumors
(RECIST) version 1.1 is required for evaluation of
response. All patients must sign informed consent
forms approved by the relevant institutional review
board.
Exclusion criteria include: prior treatment with doce-
taxel; active or recent history of hemoptysis (at least
one-half teaspoon of bright red blood per event); cen-
tral nervous system metastases; active thrombosis or
embolism; serious infection; serious uncontrolled med-
ical conditions including heart disease, diabetes, or
hypertension; uncontrolled effusion (pleural, peritoneal,
or pericardial effusion requiring drainage for symptom
management); major surgery within 4 weeks prior to
registration; minor surgical procedures, radiation ther-
apy, or transfusion within the previous 14 days; evi-
dence of interstitial pneumonitis or pulmonary fibrosis
on the baseline chest x-ray; pregnancy or lactation;
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Figure 1 WJOG 5910L treatment design. PD, progressive disease.Patient registration
After eligibility criteria are confirmed and informed con-
sent obtained, eligible patients are registered and the
planned treatment is initiated by investigators. The ac-
crual began in February 2011 and is to continue for
2 years.
Treatment plan
In this multicenter phase II trial, patients are randomly
assigned on a 1:1 basis to docetaxel or docetaxel plus
bevacizumab (Figure 1). The study focuses on the out-
come of a second bevacizumab-based line of treatment,
seeking clinical predictors that might help identify
patients likely to benefit from bevacizumab therapy be-
yond progression (Figure 2). Stratification factors were
thus chosen on the basis of the hypotheses that patients
who show progressive disease during first-line therapy
are unlikely to benefit from second-line therapy and that
bevacizumab as a maintenance therapy after treatment
with bevacizumab plus a platinum-based doublet until
disease progression may augment the efficacy of chemo-
therapy in second-line treatment. Random assignment
was stratified by (i) baseline ECOG performance status
(0 or 1 versus 2), (ii) history of treatment with EGFR
tyrosine kinase inhibitors (gefitinib or erlotinib versus
neither), (iii) duration of treatment with bevacizumab
plus a platinum-based doublet (<6 versus ≥6 weeks), and
(iv) time to disease progression after the last bevacizu-
mab administration of the first-line treatment (<3 versus
≥3 weeks). Patients treated in arm A will receive doce-
taxel (60 mg/m2) and those in arm B will receive doce-
taxel (60 mg/m2) plus bevacizumab (15 mg/kg) on day 1
every 21 days until progression or unacceptable toxicity.
Patients in arm B are allowed to receive docetaxel alone
as a result of bevacizumab-related toxicity, but they are
not allowed to receive bevacizumab alone. A computed
tomography (CT) or magnetic resonance imaging (MRI)
scan of the brain, CT scans of the chest and abdomen,
bone scan or positron emission tomography (PET) scan,
and an electrocardiogram are required before onset of
the study treatment. Patients undergo tumor assessment
at baseline, every 4 weeks during the first 12 weeks, and
every 6 weeks thereafter. Adverse events are recordedI
Docetaxel (60 mg/m2)
on day 1, every 3 weeks 
Docetaxel (60 mg/m2) plus 
bevacizumab (15 mg/kg) 



















Figure 2 Disease course patterns for first-line chemotherapy. Red arrows indicate discontinuation of first-line treatment because of PD;
broken black arrows indicate discontinuation before PD.
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icity Criteria (version 4.0).
Statistical considerations
The primary and secondary efficacy endpoint analysis
will be performed with the intent-to-treat population.
The emphasis of the efficacy analysis will be on estimat-
ing the size of the difference in treatment effect between
arm A and arm B. The sample size was calculated on
the basis of hypothesis testing in terms of PFS, which
was defined as the time from registration until disease
progression or death, whichever occurs earlier. Patients
who have not experienced progression or death by the
end of follow-up for the study will be censored on the
date of the last tumor assessment. The trial is based on
a randomized phase II screening design as described
previously [20]. A previous randomized phase II study
evaluated the efficacy of chemotherapy with or without
bevacizumab in patients with advanced nonsquamous
NSCLC who were treated with first-line chemotherapy
without bevacizumab. The primary endpoint of PFS
tended to be longer with chemotherapy plus bevacizu-
mab than for chemotherapy alone (HR, 0.66; 95% confi-
dence interval, 0.38 to 1.16) [21]. Accordingly, the
present trial is designed as a one-sided test to detect a
≥30% reduction in the HR associated with PFS favoring
the experimental arm with a type I error (alpha) rate of
0.20. The median PFS for docetaxel alone is estimated to
be 2.0 months based on the results of previous phase III
trials. According to these parameters, a total of 90 or
more events (total from both arms combined) is
required to achieve a statistical power of >80%. Taking
into account patients who prove to be ineligible or who
are lost to follow-up, the sample size is planned as 100
patients.
Conclusion
The WJOG 5910L trial is designed to examine the clin-
ical benefit and safety of continued bevacizumab treat-
ment beyond first disease progression in patients with
advanced nonsquamous NSCLC whose disease has pro-
gressed after first-line treatment with bevacizumab plusa platinum-based doublet. The information obtained by
the study may prompt early completion of the planned
patient accrual.
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